Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173244 | 0.83 | HMGCR (0.46) | HMGCRHSD17B10KDM4E | |
| SCHEMBL26022486 | 0.77 | HSP90AA1 (0.41) | HMGCRHSD17B10KDM4E | |
| SCHEMBL25530017 | 0.77 | HSP90AA1 (0.32) | — | |
| SCHEMBL25530016 | 0.77 | HSD17B10 (0.34) | HSD17B10SQORKDM4E | |
| SCHEMBL25530095 | 0.76 | — | — | |
| SCHEMBL179446 | 0.76 | HSD17B10 (0.55) | HSD17B10KDM4E | |
| SCHEMBL25530093 | 0.76 | HRH4 (0.46) | HSD17B10SQORKDM4E | |
| SCHEMBL12257766 | 0.74 | KDM4E (0.39) | HMGCRHSD17B10KDM4E | |
| SCHEMBL19154841 | 0.73 | HMGCR (0.37) | HMGCRHSD17B10SQORKDM4E | |
| SCHEMBL19051434 | 0.73 | HSD17B10 (0.42) | HMGCRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | HMGCR 3982/4885HSD17B10 4037/4885SQOR 3157/4885 |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, ROCK2, RHOT2 | HMGCR 307/4885HSD17B10 1285/4885SQOR 2498/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | HMGCR 3810/4885HSD17B10 3733/4885SQOR 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.